Biopharmaceutical Contract Manufacturing Market, 2027

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
216
Biopharmaceutical Contract Manufacturing Market, 2027

Dublin, July 06, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017-2027" report to their offering. The Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017-2027' report provides an extensive study of the contract manufacturing market for biopharmaceuticals. As the biotechnology industry continues to strive to maximize profits, outsourcing has emerged as a promising trend. The study features in-depth analysis, highlighting capabilities of a diverse set of biopharmaceutical CMOs.

One of the key focus areas of the study was to estimate size of the future opportunity for biopharmaceutical CMOs over the coming decade. In order to provide a detailed future outlook, our projections have been segmented on the basis of commonly outsourced business operations (Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs)), types of expression systems and key geographical regions. The base year for the report is 2017, and it provides a detailed market forecast for the period between 2017 and 2027. The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. For the purpose of the study, we invited more than 200 senior stakeholders in the industry to participate in a survey. This enabled us to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. In addition, the opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies). It is worth highlighting that the biopharmaceutical market is characterized by a huge unmet need for adequate manufacturing facilities and expertise. Given the inherent complexities associated with the development of biologics, the aforementioned need is likely to translate into promising business opportunities for CMOs.

In addition to other elements, it provides information on the following: - The competitive market landscape and industry analysis based on a number of parameters, such as geographical location, scale of operation, type of biologics manufactured, expression systems used, type of bioreactors used, mode of operation of bioreactors and bioprocessing capacity. - Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance, information on its manufacturing service and facilities, partnerships and recent developments. - A detailed discussion on the key enablers, including certain niche sub-segments, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market. - A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical contract service providers. - A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the market. The analysis takes into consideration the average capacities of small, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research. - Information on other aspects of biopharmaceutical outsourcing, which include the growing number of collaborations, partnerships and investments in facility expansions. - Affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Competitive Landscape 5. Biopharmaceutical Contract Manufacturing In North America 6. Biopharmaceutical Contract Manufacturing In Europe 7. Biopharmaceutical Contract Manufacturing In Asia And The Rest Of The World 8. Niche Sectors In Biopharmaceutical Contract Manufacturing 9. Case Study: Outsourcing Of Biosimilars 10. Recent Developments 11. Capacity Analysis 12. Survey Analysis 13. Opportunity Analysis 14. Swot Analysis 15. Future Of The Biopharmaceutical Cmo Market 16. Interview Transcripts 17. Appendix I Tabulated Data 18. Appendix Ii List Of Companies And Organizations - 3P Biopharmaceuticals - Aalto Scientific - AbbVie Contract Manufacturing - AbGenomics - Ablynx - Abzena - ACES Pharma - Acticor Biotech - Active Biotech - Adar Biotech - ADC Therapeutics - Adimab - Advanced BioScience Laboratories (ABL) - Advanced Biotherapeutics Consulting (ABC) - Affimed - Affinity Life Sciences - Agensys - Ajinomoto Althea - Albany Molecular Research (AMRI) - Alberta Cell Therapy Manufacturing - Alcami - Aldevron - Allele Biotechnology - Alliance Medical Products - Alligator Bioscience - Allozyne - ALMAC Group - Altaris Capital Partners - AmatsiQBiologicals - AmbioPharm - Ambrx - AmBTU - AMEGA Biotech - Amgen - Amneal Life Sciences - AMSBIO - Anogen - apceth Biopharma - Applied Biological Materials - Applied Viromics - Aptuit - Arabio - Asahi Glass - Aspyrian Therapeutics - Astellas Pharma - AstraZeneca - Asymchem - Athenex Pharma Solutions - Atlantic Bio GMP - AURA Biotechnologies - AUSTRIANOVA - AutekBio - Avecia - Avid Biologics - Avid Bioservices - Bachem - Baliopharm - Batavia Biosciences - Baxter BioPharma Solutions - Bayer - BCN Peptides - Beckman Research Institute - Beijing ABT Genetic Engineering Technology - Bharat Serums And Vaccines - BIBITEC - Bicycle Therapeutics - BINEX - Bio Elpida - Bioanalytical Sciences Department, Southern Research - BioCell - Biocon - BioConnection - Biofabri - Biogen-Idec - BioLineRx - Biological and Cellular GMP Manufacturing Facility, City of Hope - Biological E - Biological Process Development Facility, University of Nebraska - BioMARC - Biomatik - Biomay - BIOMEVA - BiondVax Pharmaceuticals - BioPharmaceuticals Australia - Biosynergy - Bio-Synthesis - BioTechLogic - BioTechnique - Biotechpharma - Biotecnol - Biotest - BioVectra - Biovian - Blue Stream Laboratories - Boehringer Ingelheim - Boehringer Ingelheim BioXcellence - Brammer Bio - Bristol-Myers Squibb - Bryllan - BSP Pharmaceuticals - Cambrex - CARBOGEN AMCIS - Catalent - Catalent Biologics - Catalent Pharma Solutions - Cedarburg Pharmaceuticals - Celgene - Cell and Gene Therapy Catapult - Cell Culture Company - Cell Essentials - Cell Therapies - Cell Therapy and Regenerative Medicine, University of Utah - Celldex Therapeutics - CELLforCURE - Cellin Technologies - Cells for Sight, Stem Cell Therapy Research Unit, University College London - Celltrion - Cellular Dynamics International (a FUJIFILM company) - Cellular Therapeutics - Cellular Therapy Integrated Service, Case Western Reserve University - Celonic - Center for Biocatalysis and Bioprocessing, University of Iowa - Center for Biomedical Engineering and Advanced Manufacturing, McMaster University - Center for Cell and Gene Processing, Takara Bio - Center for Cell and Gene Therapy, Baylor College of Medicine - Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia (CHOP) - Center of iPS Cell Research and Application, Kyoto University (CiRA) - Centre for Commercialization of Regenerative Medicine - Centrose - Century Pharmaceuticals - Cerbios-Pharma - CEVEC Pharmaceuticals - Charles River Laboratories - ChemCon - Chemi Peptides - ChemPartner - Children's GMP / GMP facility St. Jude Children's Research Hospital - ChromaCon - Cincinnati Children's Hospital Medical Center - CinnaGen - Clinical Biomanufacturing Facility, University of Oxford - Clinical Research Facility, South London and Maudsley - CMC Biologics - Cobra Biologics - Cognate BioServices - Coldstream Laboratories - Concord Biotech - Concortis - Cook Pharmica - Corden Pharma - Covance - Creative Biogene - Creative Biolabs - Cryosite - CytomX Therapeutics - Cytovance Biologics - Daiichi Sankyo - Dalton Pharma Services - Dishman Group - DMBio - Dow Pharmaceutical Solutions - Dutalys - EirGenix - Eli Lilly - Embio - EMD Serono - Emergent BioSolutions - Emerson - Encap Drug Delivery - Endo Pharmaceuticals - Epigen Biotech - Esperance Pharmaceuticals - EuBiologics - EUCODIS Bioscience - EUFETS - Eurofins Central Global Laboratory - Eurogentec - Euticals - Evonik - Fabion Pharmaceuticals - Ferro Pfanstiehl - FinVector - Formation Biologics - Formosa Laboratories - Foundation BioPharma - Fraunhofer Institute for Cell Therapy and Immunology IZI - French National Centre for Scientific Research, Université de Toulouse - Frontage Laboratories - F-star - FUJIFILM Diosynth Biotechnologies - Fusimab - Fusion Antibodies - Gadea Pharmaceutical Group - Gala Biotech - Gallus BioPharmaceuticals - Ganymed Pharmaceuticals - Gates Biomanufactuirng Facility - GE Healthcare - GEG Tech - Gene and Cell Therapy Lab, Institute of Translational Health Sciences - Gene Medicine Japan / Kobe Biomedical Accelerator - Gene Transfer Vector Core (GTVC) - Gene Transfer Vector Core, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary - Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies - Gene Vector and Virus Core, Stanford Medicine - GeneCure Biotechnologies - GeneDetect - Genentech - Genethon - GenIbet Biopharmaceuticals - Genmab - Génopoïétic - GenVec - Gilead Sciences - GIPharma - Glenmark Pharmaceuticals - Glycotope Biotechnology - GNH India - Goodwin Biotechnology - GOSH Cellular Therapy Laboratories, University College of London - GP Pharm - Grand River Aseptic Manufacturing - Great Point Partners - GreenPak Biotech - Grünenthal - GSEx, The Robinson Research Institute, University of Adelaide - GSK - GSK-Domantis - GTP Technology - Guy's and St Thomas' Facility - HALIX - Harvest Moon Pharmaceuticals - Health Biotech - Health Sciences Authority - Heidelberg Pharma - Hepalink - Hetero Drugs - Histocell - Hisun Pharmaceuticals USA - Ho Research Consortium - Hong Kong Institute of Biotechnology - Hope Center Viral Vectors Core, Washington University School of Medicine - iBIOSOURCE - Icagen - IDDI - IDT Biologika - Igenica Biotherapeutics - ImClone Systems - ImmunoGen - Immunomedics - INC Research - Indian Immunologicals - Inhibrx - Inno Biologics - Innovent Biologics - Intas Pharmaceuticals - Integrity Bio - International Joint Cancer Institute, Military Medical University - Intertek - Istituto Biochimico Italiano Giovanni Lorenzini - JHL Biotech - John Goldmann Centre for Cellular Therapy, Imperial College London - Julphar Gulf Pharmaceutical Industries - KABS Pharmaceutical Services - Kairos Therapeutics - Kamat Pharmatech - KBI Biopharma - Kemwell Biopharma - Laboratory for Cell and Gene Medicine, Stanford University - LAMPIRE Biological Laboratories - Lentigen Technology (wholly owned subsidiary of Miltenyi Biotec) - LFB BIOMANUFACTURING - Lindis Biotech - Lonza - LuinaBio - MabPlex - MacroGenics - Maine Biotechnology Services - MassBiologics - MaSTherCell - MBI International - MediaPharma - MedImmune - Medix Biochemica - Menarini Biotech - Merck - Meridian Life Science - Merrimack - Merro Pharmaceutical - Mersana Therapeutics - Merus - MGH Vector Core (Massachusetts General Hospital Neuroscience Center) - MicroBiopharm Japan - Microbix Biosystems - Millennium Pharmaceuticals - Minomic International - Mitsubishi Gas Chemical Company - Moderna Therapeutics - Molecular and Cellular Therapeutics, University of Minnesota - Molecular Partners - MolMed - MPI Research - Multispan - Mycenax Biotech - Nantes Gene Therapy Institute - Nascent Biologics - National Cancer Institute (NCI) - National Research Council of Canada - NBE Therapeutics - Neuland Laboratories - NeuroCure (Viral Core Facility) - NeuroFx - Newcastle Cellular Therapies, University of Newcastle - NextCell - NHS Blood and Transplant - NHSBT Birmingham - Nikon Cell And Gene Therapy Contract Manufacturing - Nitto Avecia Pharma Services - Nordic Nanovector - Norwegian Institute of Public Health - Nova Laboratories - Novartis - Novasep - Novex Innovations - NovImmune - Numab - Oasmia Pharmaceutical - OcellO - OctoPlus - Okairos (GSK subsidiary) - Olon - Omnia Biologics - OncoMed - OncoQuest - OsoBio - OXB Solutions (a business of Oxford BioMedica) - Oxford BioMedica - Oxford BioTherapeutics - Oxford Genetics - Pacific GMP - Paktis Antibody Services - Palatin Technologies - Pamlico BioPharma - Panacea Biotec - Paragon Bioservices - Parexel - Particle Sciences - PATH - Patheon - PCI Services (Biotec Services International) - PCT, a Caladrius company - Penn Vector Core, University of Pennsylvania - Pfizer - Pfizer CentreOne - PharmAbcine - PharmaBio - PharmaCell - Pharmedartis - PharmiCell - Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital - Philochem - PhotoBiotics - Pierre Fabre - Piramal Pharma Solutions - PlasmidFactory - Polymun Scientific - Polypeptide Group - Praxis Pharmaceutical - Precision Antibody - Precision Biologics - PREMAS Biotech - ProBioGen - Productos Bio-Logicos - Profectus BioSciences - Progenics Pharmaceuticals - ProJect Pharmaceutics - ProMab Biotechnologies - Protheragen - Provantage End-to-End Services (Merck Millipore) - PX'Therapeutics - Pyramid Labs - Quintiles - Raymond G Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia - Rayne's Cell Therapy Suite, King's College London - Receptor Logic - Redwood Bioscience - Regeneron Pharmaceuticals - Reliance Life Sciences - Rentschler Biotechnologie - Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation - Richter-Helm BioLogics - Rimedion - Robertson Clinical and Translational Cell Therapy, Duke University - Roche - Roslin Cell Therapies - Roswell Park Cancer Institute - Royal DSM - Royal Free, CCGTT - SAB Technology - SAFC - Samsung BioLogics - Sandoz - Sanofi, CEPiA (Commercial & External Partnership, Industrial Affairs) - Sanofi-Aventis - Sanquin Pharmaceutical Services - School of Medicine, University of Utah - Scientific Protein Laboratories - Sea Lane Biotechnologies - Seattle Genetics - Selexys Pharmaceuticals - Senn Chemicals - SGS Life Science Services - Shire - SignaGen Laboratories - Singota Solutions - Sirion Biotech - SNBTS Cellular Therapy Facility - Societa Italiana Corticosteroidi - Sorrento Therapeutics - Spirogen - ST Pharm - Stem CentRx - Sutro Biopharma - Sydney Cell and Gene Therapy - Symbiosis Pharmaceutical Services - Symbiosis, the Analytical Company - SynCo Bio Partners - Synergys Biotherapeutics - Syngene - SYNIMMUNE - Synthon - Sypharma - System Biosciences - Takara Bio - Takeda - The Chemistry Research Solution - The Lentiviral Laboratory, USC School of Pharmacy - The Native Antigen Company - The Vector Core, University of North Carolina - Therapure Biopharma (Therapure Biomanufacturing) - THERAVECTYS - Thermo Fisher Scientific - Toyobo Biologics - Translational Sciences - TranXenoGen - Trenzyme - Trion Pharma - Triphase Accelerator Corporation - UC Davis GMP Laboratory - UCB-Celltech - UCLA Human Gene and Cell Therapy - UMN Pharma - University of Alabama Fermentation Facility - University of Manchester - University of Oxford Clinical BioManufacturing Facility - University of Texas - Upstate Stem Cell cGMP Facility, University of Rochester - Valerion Therapeutics - Valneva - Vectalys - Vector Biolabs - Vector Core / GMP Facility, UC Davis - Vector Core Lab / Human Applications Lab, Powell Gene Therapy Center, University of Florida - Vector Core of Gene Therapy Laboratory of Nantes - Vector Production Facility, Indiana University - Vecura (Karolinska University Hospital ) - Vetter Pharma International - VGXI - Vibalogics - Vigene Biosciences - Viral Vector Core / Clinical Manufacturing Facility, Nationwide Children's Hospital - Viral Vector Core, Duke University - Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute - Viral Vector Core, University of Iowa Carver College of Medicine - Viral Vector Core, University of Massachusetts Medical School (UMMS) - Virovek - Vista Biologicals - VIVEbioTECH - Wacker Biotech - Waisman Biomanufacturing - WIL Research - Wockhardt - Wolfson Gene Therapy Unit, University College of London - WuXi AppTec - Wyeth - X-BODY Biosciences - Xellbiogene - Xencor - YposKesi - Zhejiang HISUN Pharmaceuticals - Zhengyang Gene Technology - Zumutor Biologics - Zydus Cadila - Zymeworks - ZymoGenetics - Zyngenia For more information about this report visit https://www.researchandmarkets.com/research/m...maceutical

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Biopharmaceuticals

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASMAX Unleashes Next-Level Motorcycle Comms at EICMA

Updated Category News Views 124

Transforming the Motorcycle Communication Landscape Motorcycling ain't just about the roaring engines and the rubber on the road. In the world of helmets and handlebars, some bright minds are weaving tech magic at the EICMA 2026 in Milan. ASMAX has rolled out its shiny new RoamX intercom gadget, leaving folks buzzing at Hall 6. What RoamX Brings to the Table This ain't...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 481

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Updated Category News Views 97

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Continue Reading
Strathcona Resources Q3 2026: Dividends, Deals, and Growth

Updated Category News Views 202

Digging into Strathcona's Third Quarter Strathcona Resources (TSX: SCR) is strutting its stuff again, dropping a third-quarter report that reads like a playbook for solid energy sector performance. First off, let’s talk about that dividend bump. The company decided to sprinkle some cheer with a 7% increase in its quarterly dividend, now at $0.32 per share. Not exactly...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 147

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
O-I Glass Faces Class Action: Investor Implications

Updated Category News Views 46

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Continue Reading
Onodrim Raises $300M to Propel EU Defence Future

Updated Category News Views 15

Onodrim Industries' Bold Bid to Reshape European Security Right out of the gate, Onodrim Industries is thundering onto the scene with a hefty $300 million Series A round to flex its muscles across Europe's defence and industrial sectors. This ain't your run-of-the-mill startup story. This is about flexing hard-earned capital to snap up established players and inject a...

Continue Reading
Tencent Cloud's Edge Platform Shines in New Gartner Report

Updated Category News Views 93

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 730

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding AMETEK's Short Interest and Investor Sentiment

Updated Category News Views 163

Understanding AMETEK's Short Interest AMETEK Inc (NYSE: AME) has recently seen a notable increase in short interest, with a 13.54% rise reported in its short percent of float. Currently, there are approximately 2.23 million shares sold short, equating to about 1.09% of all available regular shares. Given the current trading dynamics, traders would need about 1.43 days on...

Continue Reading
Hub Group Announces Quarterly Dividend for Investors

Updated Category News Views 126

Overview of Hub Group's Quarterly Dividend Announcement Hub Group, Inc. (NASDAQ: HUBG) has recently made headlines by declaring a quarterly cash dividend of $0.125 per share. This announcement comes directly from the company’s Board of Directors, showcasing their commitment to returning value to shareholders. The dividend reflects Hub Group's growth-focused capital...

Continue Reading
EfTEN United Property Fund's NAV Rises Slightly Amid Trends

Updated Category News Views 169

EfTEN United Property Fund's NAV Update The net asset value (NAV) of the EfTEN United Property Fund units reached 11.34 euros by the end of September, marking a modest month-on-month increase of 0.33%. This relatively small gain in NAV was influenced by the investment in EfTEN Real Estate Fund AS. The shares of this fund closed at 0.8% lower compared to the previous month...

Continue Reading
SDi Analyzes Key Trends in Lab Instrument Market for 2025

Updated Category News Views 162

Understanding the Laboratory Instruments Market Trends Strategic Directions International (SDi) has unveiled its pivotal report which dives deep into the global laboratory instrumentation market, showcasing insights about the competitive landscape. This analysis focuses on the performance of leading instrument manufacturers, providing a comprehensive understanding of...

Continue Reading
Davis Commodities Secures USD 30 Million for Growth Initiatives

Updated Category News Views 272

Davis Commodities Inc. Takes a Bold Step Forward Davis Commodities Limited (NASDAQ: DTCK) is initiating a transformative phase through the issuance of new shares valued at USD 30 million. This strategic decision marks a significant milestone for the company, aligning with its vision to enhance growth and expand operational capabilities. Advantages of Issuing New Shares...

Continue Reading